


STW  
DOCKET NO.: PHOE-0057

AT-1647#  
PATENT ✓



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Mike A. Clark

Confirmation No.: 5368

Application No.: 09/504,280

Group Art Unit: 1647


Filing Date: February 15, 2000

Examiner: Romeo, David S.

For: MODIFIED TUMOR NECROSIS FACTOR

DATE OF DEPOSIT: May 4, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

  
TYPED NAME: Patrick J. Farley  
REGISTRATION NO.: 42,524

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date

of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;  
or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☒ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☐ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).


## EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. \_\_\_\_\_, filed \_\_\_\_\_.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the EPO Supplementary European Search Report dated **March 19, 2004**, which indicates the references to be relevant.

Date: *May 4, 2004*

  
\_\_\_\_\_  
**Patrick J. Farley**  
Registration No. **42,524**

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

DOCKET NO.: PHOE-0057

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

**Mike A. Clark**

**Confirmation No.: 5368**

**Application No.: 09/504,280**

**Group Art Unit: 1647**


**Filing Date: February 15, 2000**

**Examiner: Romeo, David S.**

**For: MODIFIED TUMORS NECROSIS FACTOR**

DATE OF DEPOSIT: *May 4, 2004*

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22312-1450.

  
TYPED NAME: Patrick J. Farley  
REGISTRATION NO.: 42,524

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


**CERTIFICATION UNDER 37 CFR § 1.97(e)**

In accordance with 37 CFR § 1.97(e), certification is hereby made that:


- ☒ Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Date: May 4, 2004

  
Patrick J. Farley  
Registration No. 42,524

Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



Sheet 1 of 2

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>PHOE-0057</b>	Application No. <b>09/504,280</b>
	Applicant <b>Mike A. Clark</b>	
	Filing Date <b>February 15, 2000</b>	Group <b>1647</b>
	Confirmation No. <b>5368</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	27	Tsutsumi, Y. et al, "Molecular Design of Hybrid Tumor Necrosis Factor- $\alpha$ III: Polyethylene Glycol modified Tumor Necrosis Factor- $\alpha$ Has Markedly Enhanced Antitumor Potency due to Longer Plasma Half-Life and Higher Tumor Accumulation", <i>Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology</i> , 1996, 278(3), 1006-1011
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>



**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
**PHOE-0057**

Application No.  
**09/504,280**

Applicant  
**Mike A. Clark**

Filing Date  
**February 15, 2000**

Group  
**1647**

Confirmation No.  
**5368**

**U. S. PATENT DOCUMENTS**

Examiner Initial	Document No.	Date	Name	Class	Subclass

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	28	WO 97/32607	09/12/97	PCT		

**EXAMINER**

**DATE CONSIDERED**